101 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $200.81 $129.98B Buy
Article Searches
Is a Beat in the Cards for Allergan (AGN) in Q3 Earnings? http://www.zacks.com/stock/news/330815/is-a-beat-in-the-cards-for-allergan-agn-in-q3-earnings?cid=CS-ZC-FT-330815 Oct 24, 2018 - While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Has Amgen (AMGN) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/331088/has-amgen-amgn-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-331088 Oct 25, 2018 - Is (AMGN) Outperforming Other Medical Stocks This Year?
5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings http://www.zacks.com/stock/news/332054/5-drug-biotech-stocks-likely-to-beat-estimates-in-q3-earnings?cid=CS-ZC-FT-332054 Oct 26, 2018 - We take a look at a few stocks that might deliver an earnings beat when they report next week.
What's in the Cards for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/331996/whats-in-the-cards-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-331996 Oct 26, 2018 - Glaxo's (GSK) is expected to see strong sales in its Vaccines business segment.
Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast) https://seekingalpha.com/article/4215213-apple-looks-recharge-tech-sector-stocks-watch-podcast?source=feed_all_articles Oct 28, 2018 - Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals http://www.zacks.com/stock/news/332136/the-zacks-analyst-blog-highlights-allergan-regeneron-pharmaceuticals-amgen-alnylam-pharmaceuticals-and-amag-pharmaceuticals?cid=CS-ZC-FT-332136 Oct 29, 2018 - The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
What's in Store for Integer Holdings (ITGR) in Q3 Earnings? http://www.zacks.com/stock/news/332405/whats-in-store-for-integer-holdings-itgr-in-q3-earnings?cid=CS-ZC-FT-332405 Oct 29, 2018 - The Cardio & Vascular product line to boost Integer Holdings' (ITGR) top line in Q3. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.
Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates http://www.zacks.com/stock/news/333082/amgen-amgn-q3-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-333082 Oct 30, 2018 - Amgen (AMGN) delivered earnings and revenue surprises of 7.89% and 1.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Facebook Beats Q3 Estimates, Swings to Positive; Plus AMGN, MGM http://www.zacks.com/stock/news/333095/facebook-beats-q3-estimates-swings-to-positive-plus-amgn-mgm?cid=CS-ZC-FT-333095 Oct 30, 2018 - Facebook earnings beat by 30 cents from the Zacks consensus to $1.76 per share, and above the $1.59 in the year-ago quarter. However, revenues missed expectations of $13.81 billion, posting $13.73 billion, but are still up roughly 30% year over year.
Aging Blockbusters Send Amgen Inc.'s Bottom Line Lower https://www.fool.com/investing/2018/10/30/aging-blockbusters-send-amgen-incs-bottom-line-low.aspx?source=iedfolrf0000001 Oct 30, 2018 - New drug launches weren't quite enough to offset losses posted by aging blockbusters.

Pages: 123456...11

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $72.78 $94.35B
BIIB Biogen Inc. NASDAQ $334.44 $67.37B
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Amgen
AMGN - Google Finance https://www.google.com/finance?q=AMGN Industry related info and international coverage Summary News
AMGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=AMGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options